Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their trial from late-stage studies by Regeneron and Lilly by focusing  on higher risk patients.

Vir Biotechnology Inc. (NASDAQ:VIR) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Monday the dosing of the first patient in the Phase II/III COMET-ICE study of VIR-7831 to prevent hospitalization in COVID-19 patients with mild to moderate disease (see “Speeding COVID-19 mAbs into Phase II with $250M GSK Investment”)...